Concurrent Investment Advisors LLC Raises Stock Position in Abbott Laboratories $ABT

Concurrent Investment Advisors LLC raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 23.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,784 shares of the healthcare product maker’s stock after purchasing an additional 17,137 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Abbott Laboratories were worth $11,124,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Generali Investments Management Co LLC grew its position in shares of Abbott Laboratories by 13.4% in the 4th quarter. Generali Investments Management Co LLC now owns 27,936 shares of the healthcare product maker’s stock worth $3,500,000 after buying an additional 3,306 shares during the period. ProVise Management Group LLC lifted its stake in Abbott Laboratories by 18.8% during the 4th quarter. ProVise Management Group LLC now owns 3,188 shares of the healthcare product maker’s stock valued at $399,000 after acquiring an additional 504 shares during the period. TBH Global Asset Management LLC lifted its stake in Abbott Laboratories by 3.4% during the 4th quarter. TBH Global Asset Management LLC now owns 4,949 shares of the healthcare product maker’s stock valued at $620,000 after acquiring an additional 164 shares during the period. Segment Wealth Management LLC lifted its stake in Abbott Laboratories by 15.8% during the 4th quarter. Segment Wealth Management LLC now owns 7,830 shares of the healthcare product maker’s stock valued at $981,000 after acquiring an additional 1,070 shares during the period. Finally, Golden Reserve Retirement LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter worth approximately $560,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,055 shares of company stock valued at $353,097 in the last three months. 0.46% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ABT shares. Jefferies Financial Group dropped their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a report on Friday, April 17th. UBS Group reduced their price objective on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Oppenheimer reduced their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Evercore cut their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Finally, TD Cowen cut their target price on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $119.43.

Abbott Laboratories Stock Down 1.4%

Shares of ABT opened at $91.16 on Friday. The firm has a market capitalization of $158.76 billion, a P/E ratio of 25.53, a P/E/G ratio of 1.54 and a beta of 0.79. Abbott Laboratories has a 12-month low of $90.72 and a 12-month high of $139.06. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The firm has a fifty day moving average price of $105.96 and a 200-day moving average price of $117.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is presently 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.